Danazol and the premenstrual syndrome.

In: Postgraduate medical journal · 1979 · vol. 55 Suppl 5 , pp. 87–9 · PMID:395526 · W2416428440
article OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-12

Danazol, an antigonadotrophin, was tested for premenstrual syndrome, showing partial benefit in severe cases but significant side effects in new patients, indicating its use for resistant symptoms, especially with breast tenderness.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol as a powerful antigonadotrophin is a logical mode of treatment for patients with premenstrual symptoms. Its preliminary use in a dose 200-800 mg daily is reported. Two groups of patients were treated and of 12 patients with severe symptoms (Group I) six benefited from treatment. The second group (Group II) presenting as fresh cases were given 400 mg daily as the first or second choice of treatment. This group had a high drop out rate and any benefit from treatment was marred by the side effects. Danazol will continue to be used where the symptoms are resistant to other treatment, especially when breast tenderness is predominant. The dose should be the minimum required for relief of symptoms.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK